Bausch Health vs Pfizer: Founders, CEOs and History
Bausch Health was founded in 1994 by Eugene Melnyk, Milan Panic and is led by Thomas J. Appio. Pfizer was founded in 1849 by Charles Pfizer, Charles Erhart and is led by Albert Bourla.
Company facts
Bausch Health
- Founded
- 1994
- Headquarters
- Laval, Quebec, Canada
- Current CEO
- Thomas J. Appio
- Employees
- 20,300
Pfizer
- Founded
- 1849
- Headquarters
- New York, New York
- Current CEO
- Albert Bourla
- Employees
- 75,000
Founders
Bausch Health
Eugene Melnyk
Eugene Melnyk built Biovail into Canada's largest publicly traded pharmaceutical company, with revenue growing from about $19M in 1995 to roughly $1.07B in 2006.
Milan Panic
Milan Panic ran ICN Pharmaceuticals for four decades and made it known for the broad-spectrum antiviral ribavirin, sold as Virazole.
Pfizer
Charles Pfizer
Pfizer possesses a historic, immigrant founding story, rooted entirely in the rapid industrial expansion of 19th-century Brooklyn and defined by an effective, intensely meticulous German chemist and his ambitious confectioner cousin.
Charles Erhart
Charles Erhart's role in Pfizer's founding is less celebrated than his cousin's, partly because the company carries Charles Pfizer's name and partly because his commercial contributions were less visible than the scientific achievements that drove the company'…
CEOs and their tenures
Bausch Health
- J. Michael Pearson2008–2016
Former Chief Executive Officer
Pearson, a former McKinsey director, became chief executive of Valeant Pharmaceuticals effective February 1, 2008 and ran the company through the September 2010 merger with Canada's Biovail until early May 2016.
Source - Joseph C. Papa2016–2022
Former Chief Executive Officer
Papa, previously chief executive of Perrigo, was named chairman and CEO in April 2016 and took over in early May 2016, inheriting about $30B of debt, an SEC investigation and congressional scrutiny of Valeant-era drug pricing.
Source - Thomas J. Appio2022–present
Chief Executive Officer
Appio became chief executive officer and a director in May 2022, succeeding Joseph Papa.
Source
Pfizer
- Ian Read2010–2018
Chief Executive Officer
He ruthlessly cut R&D spending and eliminated tens of thousands of jobs, significantly boosting short-term earnings per share despite massive patent cliffs for blockbuster drugs like Lipitor.
Source - Albert Bourla2019–present
Chairman and Chief Executive Officer
A veterinarian by training who joined Pfizer Animal Health in 1993, Bourla became CEO on January 1, 2019 and Chairman in 2020.
Source - Dave Denton2022–2026
Chief Financial Officer
As CFO, he aggressively restructured the balance sheet following the Seagen acquisition, prioritizing debt reduction while defending the dividend.
Source - Chris Boshoff2025–present
Chief Scientific Officer and President, Research & Development
He completely restructured the research and development organization to focus on antibody-drug conjugates (ADCs), aggressively expanding Pfizer's pipeline of cancer therapeutics.
Source - Cecile Guegan2026–present
Interim Chief Financial Officer
She modernized the company's internal auditing and compliance structures, ensuring rapid but safe clinical execution for high-priority vaccine programs.
Source
Timeline: Bausch Health and Pfizer side by side
1849Pfizer
Pfizer Founded
Charles Pfizer and Charles Erhart founded the company in Brooklyn.
1944Pfizer
Penicillin Scale-Up
Pfizer helped industrialize penicillin production during World War II.
1959Bausch Health
Milan Panic founds ICN Pharmaceuticals
Milan Panic, a Yugoslav immigrant to California, founded ICN Pharmaceuticals in 1959 and ran it for four decades. ICN is the predecessor of Valeant Pharmaceuticals and of today's Bausch Health.
1994Bausch Health
Biovail Corporation International formed in Canada
On March 29, 1994 Eugene Melnyk consolidated his Canadian drug-delivery business by amalgamating Trimel Corporation with its subsidiary to create Biovail Corporation International, the legal entity that files today as Bausch Health Companies Inc.
1998Pfizer
Viagra Approved
The FDA approved Viagra in 1998.
2000Pfizer
Warner-Lambert Deal
Pfizer acquired Warner-Lambert, adding Lipitor.
2003Bausch Health
ICN renames itself Valeant Pharmaceuticals
ICN Pharmaceuticals, then based in Costa Mesa, California, took the Valeant Pharmaceuticals name in November 2003 to distance itself from the governance fights of the Panic era.
2008Bausch Health
J. Michael Pearson becomes chief executive
Valeant appointed former McKinsey director J. Michael Pearson as chief executive effective February 1, 2008, succeeding Timothy C. Tyson. Pearson replaced internal research spending with debt-funded acquisitions of marketed drugs.
2009Pfizer
Wyeth Acquired
Pfizer bought Wyeth in 2009 for about $68 billion.
2010Bausch Health
Biovail and Valeant complete their merger
The merger of Biovail Corporation and Valeant Pharmaceuticals International closed on September 28, 2010. The combined company kept the Valeant name and Pearson as chief executive but was incorporated in Canada.
2011Bausch Health
Ortho Dermatologics bought from Johnson and Johnson
Valeant agreed to acquire the U.S. Ortho Dermatologics assets from Janssen Pharmaceuticals, a Johnson and Johnson company, for about $345M in cash, building the dermatology franchise.
2013Bausch Health
Bausch + Lomb acquired for $8.7 billion
Valeant agreed in May 2013 to buy eye-health company Bausch + Lomb from Warburg Pincus for $8.7B in cash, adding contact lenses, lens care, ophthalmic drugs and surgical devices.
2015Bausch Health
Salix acquisition closes at about $11.1 billion
Valeant completed its tender offer for Salix Pharmaceuticals on April 1, 2015 at $173 per share, about $11.1B in equity value and roughly $15.8B including debt, gaining the Xifaxan franchise.
2015Bausch Health
Drug pricing and Philidor scandal breaks
Congressional investigators pressed Valeant over 525% and 212% increases on the heart drugs Isuprel and Nitropress, bought in February 2015, and over its undisclosed ties to the Philidor mail-order pharmacy.
2016Bausch Health
Joseph Papa replaces Pearson as chief executive
Valeant named Perrigo chief executive Joseph C. Papa as chairman and CEO on April 25, 2016, and he took over in early May 2016 with about $30B of debt outstanding.
2017Bausch Health
Skincare brands and Dendreon sold to cut debt
Valeant sold the CeraVe, AcneFree and AMBI skincare brands to L'Oreal for about $1.3B and the Dendreon cancer unit to China's Sanpower Group for about $820M, using the proceeds to repay debt.
2018Bausch Health
Company renamed Bausch Health Companies Inc.
The name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. was completed on July 13, 2018, and the shares began trading as BHC on the NYSE and TSX on July 16, 2018.
2019Pfizer
Albert Bourla becomes CEO
Albert Bourla became CEO of Pfizer in 2019. A veterinarian by training who joined Pfizer Animal Health in 1993, Bourla became CEO on January 1, 2019 and Chairman in 2020.
2020Bausch Health
SEC settlement closes the Philidor accounting case
On July 31, 2020 Bausch Health agreed to pay a $45M civil penalty to settle SEC charges of improper revenue recognition and misleading disclosures tied to Philidor. Former chief executive J. Michael Pearson and two other executives also settled.
2020Pfizer
BioNTech COVID Vaccine Partnership
Pfizer and BioNTech brought Comirnaty through emergency authorization.
2022Bausch Health
Bausch + Lomb listed on the NYSE and TSX
Bausch + Lomb common stock began trading under the ticker BLCO on May 6, 2022, and a Bausch Health subsidiary sold 35,000,000 Bausch + Lomb shares in the offering. Bausch Health retained about 88% of the eye-health company and still consolidates it. Thomas J.
2023Pfizer
Seagen Acquisition
Pfizer completed the $43 billion Seagen acquisition.
2025Bausch Health
DURECT acquired and record annual revenue reported
Bausch Health closed the DURECT acquisition on September 11, 2025 for about $63M upfront, completed Solta Medical's Chinese aesthetics distribution purchase on December 1, 2025, and reported FY2025 revenue of $10.266B, up 7%, with net income attributable to Ba…
2025Pfizer
Chris Boshoff Becomes CSO
Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.
2025Pfizer
Metsera Acquisition
Pfizer completed its acquisition of obesity drug developer Metsera in November 2025 for up to about $10 billion including CVRs.
2025Pfizer
FY2025 Revenue Base
Pfizer reported $62.579 billion of FY2025 revenue.
2026Bausch Health
RED-C trials miss endpoints and trigger a $1.4 billion charge
In January 2026 the two Phase 3 RED-C trials of amorphous-rifaximin soluble solid dispersion for primary prevention of hepatic encephalopathy missed their primary endpoints.
2026Bausch Health
Second-quarter 2026 revenue of $2.85 billion and raised guidance
Bausch Health reported second-quarter 2026 revenue of $2.85B, up 13%, net income attributable to Bausch Health of $258M and adjusted EBITDA of $1.075B, and raised its full-year 2026 revenue, adjusted EBITDA and cash flow guidance.
2026Pfizer
Innovent Oncology Collaboration
Pfizer signed a 12-program cancer collaboration with Innovent Biologics: $650 million upfront and up to $9.85 billion in milestones.
Acquisitions
Bausch Health
- DURECT Corporation2025$63M
- Shibo Zhenmei aesthetics distribution business2025Undisclosed
- Salix Pharmaceuticals2015$11.1B
- Bausch + Lomb Holdings2013$8.7B
- Ortho Dermatologics2011$345M
- Sanitas2011Undisclosed
Pfizer
- Metsera, Inc.2025$7B
- Seagen Inc.2023$43B
- Medivation Inc.2016$14B
- Wyeth2009$68B
- Pharmacia Corporation2003$60B
- Warner-Lambert Company2000$111B
Questions about Bausch Health vs Pfizer
Who is the CEO of Bausch Health Companies Inc. and Pfizer Inc.?
Bausch Health Companies Inc. is led by Thomas J. Appio and Pfizer Inc. is led by Albert Bourla. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bausch Health Companies Inc. founded vs Pfizer Inc.?
Pfizer Inc. was founded in 1849 — 145 years before Bausch Health Companies Inc., which was founded in 1994. Pfizer Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Bausch Health Companies Inc..
How many employees does Bausch Health Companies Inc. have compared to Pfizer Inc.?
Bausch Health Companies Inc. employs approximately 20,300 people, while Pfizer Inc. employs approximately 75,000. Pfizer Inc. has the larger workforce at 75,000 employees, compared to Bausch Health Companies Inc.'s 20,300. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bausch Health Companies Inc. and Pfizer Inc. headquartered?
Bausch Health Companies Inc. is headquartered in Canada and Pfizer Inc. is headquartered in United States. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bausch Health Companies Inc. and Pfizer Inc.?
Bausch Health Companies Inc. was founded by Eugene Melnyk, Milan Panic. Pfizer Inc. was founded by Charles Pfizer, Charles Erhart.
Which company has a longer operating history — Bausch Health Companies Inc. or Pfizer Inc.?
Pfizer Inc. has been operating for approximately 177 years, making it the more established of the two companies. Bausch Health Companies Inc. has been in operation for around 32 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bausch Health vs Pfizer overview